Journal article · 2026 · Open access

A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case–control study

Shaun O’Hagan, Steve Cunningham, Simon B. Drysdale, Helen Elizabeth Groves, Samantha Hunt, Dalia Iskander, Xinxue Liu, Mark David Lyttle, Chengetai D Mpamhanga, Thomas Waterfield, Thomas Williams, Robin D. Marlow and 132 more

The Lancet Child & Adolescent Health, 10(9), 637–646 · Published 1 July 2026 · DOI 10.1016/s2352-4642(26)00134-3

Open full textCite this paper

In brief

“A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case–control study” is a 2026 journal article by Shaun O’Hagan and 143 co-authors, published in The Lancet Child & Adolescent Health. OpenAlex counts 4 citations as of 18 November 2026, which puts it in the top 3% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at The Lancet Child & Adolescent Health.

Citations
4
Most cited in
2026 (4)
Field-weighted impact
13.31
References
21
Authors
144

Abstract

BACKGROUND: In late summer, 2024, the UK introduced the maternal bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine for all pregnant individuals at a gestation of 28 weeks or more. After an initial catch-up phase, the maternal RSVpreF programme transitioned to year-round delivery, and in late summer, 2025, nirsevimab replaced palivizumab for infants at high risk of severe RSV disease. We aimed to estimate the protection provided by maternal RSVpreF against hospital admission with RSV in infants up to the age of 6 months, and to assess the overall performance of the UK RSV prevention programme once this had entered a steady state. METHODS: We conducted a national, multicentre, prospective, test-negative, case-control study at 37 BronchStop hospital sites in the UK. Patient and public involvement from a group of parents informed study protocol design. Included patients were prospectively enrolled infants aged 6 months or younger at the time of hospital admission with acute lower respiratory tract infection (ALRI) and tested for RSV. Test-positive infants (case patients) were defined as those admitted with a positive RSV test. Test-negative infants (control patients) were defined as those who tested negative for RSV. Infants were followed up until hospital discharge or death while an inpatient. The primary outcome was infant hospital admission with RSV-associated ALRI in infants born at a gestation of 28 weeks or more who did not receive nirsevimab postnatally. Primary vaccine effectiveness was calculated with the use of a conditional logistic regression model adjusted by site, calendar month of attendance, gestational age at birth, socioeconomic status, age at admission, and breastfeeding status. This study was registered with ClinicalTrials.gov, NCT04959734. FINDINGS: Between Sept 2, 2025, and Jan 31, 2026, 1356 infants were admitted to participating sites and screened for eligibility, 694 of whom were included in the primary analysis (429 RSV-positive infants and 265 RSV-negative infants). Median age was 2·2 months (IQR 1·3-3·9) for RSV-positive infants and 1·7 months (1·0-3·3) for RSV-negative infants. 394 (57%) of 694 infants were male and 300 (43%) were female. Ethnicity data were available for 693 mothers, of whom 538 (78%) identified as being of White ethnicity. The mothers of 161 (38%) RSV-positive infants and 175 (66%) RSV-negative infants had received the RSVpreF vaccine before delivery. The adjusted vaccine effectiveness of maternal RSVpreF vaccination for preventing infant hospital admission was 61% (95% CI 38-75) for infants aged up to 6 months, and 76% (54-87) for infants aged up to 3 months. The overall effectiveness of the UK RSV prevention programme was 61% (39-75) through to age…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

O’Hagan, S., Cunningham, S., Drysdale, S. B., Groves, H. E., Hunt, S., Iskander, D., Liu, X., Lyttle, M. D., Mpamhanga, C. D., Waterfield, T., Williams, T., Marlow, R. D., Roland, D., Middleton, C. M., Connon, M., Paxton, J. M., Thomson, N., Tolhurst-Cleaver, M., Siner, S., . . . Adnan, S. (2026). A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case–control study. The Lancet Child & Adolescent Health, 10(9), 637–646. https://doi.org/10.1016/s2352-4642(26)00134-3

MLA 9

O’Hagan, Shaun, et al. “A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case–control study.” The Lancet Child & Adolescent Health, vol. 10, no. 9, 2026, pp. 637–646. https://doi.org/10.1016/s2352-4642(26)00134-3.

Chicago

O’Hagan, Shaun, Steve Cunningham, Simon B. Drysdale, Helen Elizabeth Groves, Samantha Hunt, Dalia Iskander, Xinxue Liu, et al. 2026. “A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case–control study.” The Lancet Child & Adolescent Health 10 (9): 637–646. https://doi.org/10.1016/s2352-4642(26)00134-3.

Harvard

O’Hagan, S. et al. (2026) ‘A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case–control study’, The Lancet Child & Adolescent Health, 10(9), pp. 637–646. doi:10.1016/s2352-4642(26)00134-3.

IEEE

S. O’Hagan et al., “A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case–control study,” The Lancet Child & Adolescent Health, vol. 10, no. 9, pp. 637–646, 2026, doi: 10.1016/s2352-4642(26)00134-3.

BibTeX

@article{ohagan2026national,
  title     = {{A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case–control study}},
  author    = {O’Hagan, Shaun and Cunningham, Steve and Drysdale, Simon B. and Groves, Helen Elizabeth and Hunt, Samantha and Iskander, Dalia and Liu, Xinxue and Lyttle, Mark David and Mpamhanga, Chengetai D and Waterfield, Thomas and Williams, Thomas and Marlow, Robin D. and Roland, Damian and Middleton, Catriona Mary and Connon, Maggie and Paxton, Jill M and Thomson, Nicola and Tolhurst-Cleaver, Meriel and Siner, Sarah and Fletcher, Stephen and Geoghegan, Karen and Tremarco, Laura Ann and Diaba, Cynthia Dzokoto and Iheanetu-Oguejiofor, Chidinma Joanne and Dolma, Lobsong and Ruo, Stephen Waithaka and Berg, Richard Benjamin Stuart and Kehtarnavaz, Elena and Whitehouse, Abigail Louise and Wild, Grace E and others},
  journal   = {The Lancet Child \& Adolescent Health},
  year      = {2026},
  volume    = {10},
  number    = {9},
  pages     = {637--646},
  doi       = {10.1016/s2352-4642(26)00134-3},
  url       = {https://doi.org/10.1016/s2352-4642(26)00134-3}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Epidemiology › Respiratory viral infections research

  • respiratory syncytial virus
  • RSVpreF vaccine
  • vaccine effectiveness
  • nirsevimab
  • palivizumab
  • acute lower respiratory tract infection
  • infants under 6 months
  • test-negative case-control

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

O’Hagan, S., Cunningham, S., Drysdale, S. B., Groves, H. E., Hunt, S., Iskander, D., Liu, X., Lyttle, M. D., Mpamhanga, C. D., Waterfield, T., Williams, T., Marlow, R. D., Roland, D., Middleton, C. M., Connon, M., Paxton, J. M., Thomson, N., Tolhurst-Cleaver, M., Siner, S., . . . Adnan, S. (2026). A national programme of bivalent prefusion F vaccination in pregnancy and protection against respiratory syncytial virus hospitalisation in infants until age 6 months in the UK: a multicentre, prospective, test-negative, case–control study. The Lancet Child & Adolescent Health, 10(9), 637–646. https://doi.org/10.1016/s2352-4642(26)00134-3

How many times has this paper been cited?

4 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Lancet Child & Adolescent Health: sign in and open the full text from this page.

Who wrote this paper?

Shaun O’Hagan, Steve Cunningham, Simon B. Drysdale, Helen Elizabeth Groves, Samantha Hunt, Dalia Iskander, Xinxue Liu, Mark David Lyttle, Chengetai D Mpamhanga, Thomas Waterfield, Thomas Williams, Robin D. Marlow and 132 more.

What is the DOI of this paper?

10.1016/s2352-4642(26)00134-3, permanently at https://doi.org/10.1016/s2352-4642(26)00134-3. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.